Hormone replacement therapy benefits meibomian gland dysfunction in perimenopausal women. Issue 31 (August 2016)

• Record Type: Journal Article
• Authors: Jin, Xiuming; Lin, Zhenyun; Liu, Yufang; Lin, Lin; Zhu, Binbin
• Other Names: Abdulrahman. Khaled section editor.
• Is Part Of: Medicine. Volume 95:Issue 31(2016)
• Publication Date: 2016-08
• Subjects: dry eye -- hormone replacement therapy -- meibomian gland dysfunction -- perimenopause -- women; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000004268
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Meibomian gland dysfunction (MGD) is believed to be the leading cause of dry eye (DE) disease worldwide. The connection between aging and MGD has long been recognized. However, few studies have addressed the relationship between MGD and hormone replacement therapy (HRT) in perimenopausal women, and not have examined the prevalence of MGD in perimenopausal women. The purpose of this study was to address and evaluate the possible relationship between MGD and HRT in perimenopausal women. The results suggest that perimenopausal women have a high prevalence of DE related to perimenopausal symptoms. The study also shows that perimenopausal women who use HRT can gain benefits for DE as well as for perimenopausal symptoms. Physicians caring for women who are experiencing DE related to perimenopausal symptoms should consider HRT.